Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obsidian Therapeutics
Biotech
Obsidian leverages Galera reverse merger to go public
Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.
Will Maddox
Apr 14, 2026 11:20am
Former Arena CEO takes over new RNA biotech—Chutes & Ladders
May 26, 2023 9:30am
Bristol Myers inks extension to Obsidian cell therapy pact
Oct 27, 2022 10:25am
Obsidian bags $115M to untether cell therapy from toxic sidekick
Sep 9, 2021 8:00am
Vertex taps Obsidian in controllable genetic medicines deal
Apr 22, 2021 10:23am
Bristol Myers exercises option on Obsidian's CD40L cell therapy
Sep 15, 2020 9:25am
